https://www.biospace.com/employer/400405/bridgebio BridgeBio en-US Thu, 05 Sep 2019 14:05:48 GMT https://www.biospace.com/bridgebio-launches-new-subsidiary-to-tackle-limb-girdle-muscular-dystrophy Alex Keown BridgeBio launched Charlotte, N.C.-based ML Bio Solutions to develop the LGMD2i asset BBP-418, a substrate supplementation therapy. Thu, 05 Sep 2019 14:05:48 GMT https://www.biospace.com/bridgebio-launches-new-subsidiary-to-tackle-limb-girdle-muscular-dystrophy https://www.biospace.com/a-look-at-5-big-and-interesting-biotech-ipos-for-2019 Mark Terry Here’s a look at some of the biggest U.S. Nasdaq-based initial public offerings in 2019 and some of the more intriguing ones. Fri, 20 Dec 2019 15:09:18 GMT https://www.biospace.com/a-look-at-5-big-and-interesting-biotech-ipos-for-2019 https://www.biospace.com/clinical-catch-up-january-6-10-2020 Mark Terry The first full business week of the new year began with plenty of clinical trial news. Here’s a look. Fri, 10 Jan 2020 15:41:45 GMT https://www.biospace.com/clinical-catch-up-january-6-10-2020 https://www.biospace.com/jp-morgan-roundup-jan-13 Alex Keown With the J.P. Morgan Healthcare Conference in full swing, companies did not waste time in announcing deals and providing updates to their pipelines. BioSpace takes a look at some of the announcements made on day one of the annual conference in the Bay Area. Mon, 13 Jan 2020 19:35:22 GMT https://www.biospace.com/jp-morgan-roundup-jan-13 https://www.biospace.com/biospace-movers-and-shakers-feb-28 Alex Keown Biopharma and life sciences strengthen their executive leadership teams and boards with this week's Movers & Shakers. Thu, 27 Feb 2020 17:48:33 GMT https://www.biospace.com/biospace-movers-and-shakers-feb-28 https://www.biospace.com/how-covid-19-is-affecting-clinical-trials-and-drug-supplies-from-biotech-bay-companies Chelsea Weidman Burke, M.S. Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19. Thu, 04 Jun 2020 17:33:08 GMT https://www.biospace.com/how-covid-19-is-affecting-clinical-trials-and-drug-supplies-from-biotech-bay-companies https://www.biospace.com/biospace-movers-and-shakers-june-26 Alex Keown Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers. Thu, 25 Jun 2020 18:06:01 GMT https://www.biospace.com/biospace-movers-and-shakers-june-26 https://www.biospace.com/bridgebio-acquires-remaining-stake-in-eidos-to-tune-of-175-million Brandon May The transaction between BridgeBio and Eidos is expected to close in the first quarter of 2021. Mon, 05 Oct 2020 18:19:06 GMT https://www.biospace.com/bridgebio-acquires-remaining-stake-in-eidos-to-tune-of-175-million https://www.biospace.com/lianbio-is-driving-innovation-in-china-with-next-gen-ceo-yizhe-wang Heather McKenzie Wang, who has played a key role in the development of more than 25 innovative medicines at Eli Lilly and GlaxoSmithKline, made him the ideal fit for the company’s next chapter. Mon, 24 May 2021 13:09:33 GMT https://www.biospace.com/lianbio-is-driving-innovation-in-china-with-next-gen-ceo-yizhe-wang https://www.biospace.com/fda-approves-bridgebio-qed-therapeutics-truseltiq-for-cholangiocarcinoma Mark Terry The FDA approves Truseltiq for patients with previously-treated locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. Tue, 01 Jun 2021 13:34:12 GMT https://www.biospace.com/fda-approves-bridgebio-qed-therapeutics-truseltiq-for-cholangiocarcinoma